|
業務類別
|
-- |
|
業務概覽
|
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States. |
| 公司地址
| Via Antonio Meucci 3, Bresso, Milan, ITA, 20091 |
| 電話號碼
| +39 26103461 |
| 傳真號碼
| +39 261034654 |
| 公司網頁
| https://www.newron.com |
| 員工數量
| 22 |
| Mr. Stefan Weber |
Director and Chief Executive Officer |
-- |
31/03/2025 |
|
|
| Ms. Margarita Chavez, J.D. |
Independent Director |
31/03/2025 |
| Mr. Christopher Martin |
Chairman of the Board |
31/03/2025 |
| Dr. Patrick J. Langlois, PhD |
Independent Director |
31/03/2025 |
| Dr. Luca Benatti, PhD |
Independent Director |
31/03/2025 |
| Ms. Gillian Dines |
Independent Director |
31/03/2025 |
| Mr. Stefan Weber |
Director and Chief Executive Officer |
31/03/2025 |
|
|
|
|
